Lymphoid and Myeloid Malignancies: Immunomodulatory Drugs, Biomarker and Importance of Cereblon CRBN-Associated Proteins

Delve into the intricate world of Lymphoid and Myeloid Malignancies with Lymphoid and Myeloid Malignancies: Immunomodulatory Drugs, Biomarkers, and Importance of Cereblon CRBN-Associated Proteins. This comprehensive book explores the forefront of cancer treatment, focusing on immunomodulatory medications and the pivotal role of CRBN-associated proteins like IMiDs and CELMoDs. Beginning with an insightful introduction, the text progresses to examine the impact of IMiDs on B cell malignancies, highlighting their influence on the tumor microenvironment and mechanisms of NK cell death. Crucial discussions include clinical assessments of IMiD and CELMoD efficacy in CLL and B cell NHL, alongside biomarkers for treatment response and future therapeutic combinations. Monoclonal antibodies and CAR-T cell therapies are also explored as potent tools in cancer treatment. Special emphasis is placed on CRBN's function within the ubiquitin-proteasome complex and its significance as a biomarker for lenalidomide response or resistance in multiple myeloma. From innovative therapies for chronic myeloma to complex AML and high-risk MDS treatments, each chapter is meticulously researched and designed to provide clinicians, researchers, and students with a thorough understanding of current advancements and future directions in hematology and oncology. Lymphoid and Myeloid Malignancies is a pivotal resource for navigating the complexities of hematologic cancers, offering insights that pave the way for enhanced patient outcomes and novel therapeutic strategies.